Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Obatoclax may stop the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer.
Bortezomib and obatoclax may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving obatoclax together with bortezomib may kill more cancer cells.
This phase I/II trial is studying the side effects and best dose of obatoclax when given
together with bortezomib and to see how well they work in treating patients with aggressive
relapsed or recurrent non-Hodgkin lymphoma.